摘要
目的探讨NLRP3炎症小体及其下游炎症因子在动脉粥样硬化炎症反应中的作用。方法选择氧化低密度脂蛋白(ox-LDL)作用于人单核细胞系THP-1,经Western blot法检测NLRP3及其下游炎症因子半胱天冬酶-1(Caspase-1)、白介素-1β(IL-1β)和白介素-18(IL-18)的表达;并采用Si RNA技术下调空白处理组(Blank组)和ox-LDL处理组NLRP3基因表达,分别检测以上指标。结果与空白处理组相比,50 mg/L、100 mg/L、150 mg/L的ox-LDL作用于单核细胞后可促进NLRP3的表达,NLRP3下游的Caspase-1、IL-1β和IL-18表达水平与NLRP3表达一致,表达也均明显升高,差异均具有统计学意义(P<0.05)。NLRP3小干扰RNA(SC-45469)转染后,Blank组与ox-LDL组的NLRP3及其下游炎症因子Caspase-1、IL-1β和IL-18的表达均有显著下降(P<0.05);而转染后Blank组与ox-LDL组各指标下降率组间比较差异均无统计学意义(P>0.05)。结论 NLRP3炎症小体参与动脉粥样硬化发生发展的过程,其可能通过改变ox-LDL的表达水平,诱发炎症相关因子Caspase-1、IL-1β和IL-18的分泌来调节,NLRP3炎症小体具有成为临床上防治动脉粥样硬化的新靶点的重要潜力。
Objective To investigate the roles of NLRP3 inflammasome and its downstream inflammatory cytokines in inflammatory response of atherosclerosis. Methods NLRP3 and its downstream inflammatory cytokines of Caspase-1, interleukin-1 beta（IL-1β） and interleukin-18（IL-18） expression were detected by western blot with oxidized low-density lipoprotein（ox-LDL） in human monocytic THP-1 cell line. Si RNA technology was applied to down-regulate the expression of NLRP3 gene in blank treatment group（blank group） and ox-LDL treatment group,and the above indicators were detected. Results Compared with the blank group, ox-LDL（50 mg/L, 100 mg/L and150 mg/L） in the mononuclear cells can significantly promote the expression of NLRP3, as well as its downstream in-flammatory cytokines of Caspase-1, IL-1 β and IL-18（P0.05）. After transfection of Si RNA（SC-45469）, the expression of NLRP3 and Caspase-1, IL-1 β and IL-18 in blank group and ox-LDL treament group were significantly decreased（P0.05）, but the inhibition rate of each index showed no significant difference between the two groups（P0.05）. Conclusion NLRP3 inflammasome is involved in the development of atherosclerosis by changing the expression of ox-LDL and inducing the secretion of inflammation-related factors（Caspase-1, IL-1β and IL-18）, which has potential to become the new target for the prevention and treatment of atherosclerosis.
作者
黄巧玲
覃聪
黄广群
HUANG Qiao-ling QIN Cong HUANG Guang-qun.(Department of Clinical Laboratory, Laibin City Hospital of Traditional Chinese Medicine, Laibin 546100, Guangxi, CHINA)
出处
《海南医学》
CAS
2017年第1期86-88,共3页
Hainan Medical Journal
作者简介
通讯作者：黄巧玲。E-mail：qiaolhuang@163．com
